Clinical Trial Update: Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) [Phase 3]

View source ↗

Summary

Phase 3 trial (OVA-302) evaluating Gleolan (5-ALA) for fluorescence-guided visualization in newly diagnosed or recurrent ovarian cancer is currently recruiting.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Gleolan (5-aminolevulinic acid hydrochloride)

Snippet

Sponsor: NX Development Corp | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING